We are analyzing https://link.springer.com/article/10.1007/s00592-013-0504-8.

Title:
Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials | Acta Diabetologica
Description:
Recent epidemiological data have contributed to the formulation of the hypothesis about the long-term safety of pioglitazone, a thiazolidinedione (TZD), with respect to malignancies, in particular bladder cancer. The primary aim of this meta-analysis of randomized clinical trials, not designed a priori to test this hypothesis, was to explore whether TZDs affect the risk of cancer. A meta-analysis was performed including published and unpublished randomized trials with a duration of at least 52 weeks, enrolling patients with or without diabetes, comparing TZDs with either placebo or other drug therapies on various different outcomes. We found 22 trials reporting at least one cancer and enrolling 13,197 patients to TZD (pioglitazone: n = 3,710 and rosiglitazone: n = 9,487) and 12,359 to placebo or active comparator groups. The mean follow-up was 26.1 months. Overall, those assigned at random to TZDs had a significant reduction (MH-OR 0.85 [0.73–0.98]; p = 0.027) in the incidence of malignancies, with no significant difference in effect between pioglitazone and rosiglitazone. Specifically, subgroup analyses showed a significant reduction for rosiglitazone (MH-OR 0.82 [0.69–0.98]; p = 0.029), but not for pioglitazone (MH-OR 0.66 [0.34–1.28]; p = 0.22). In further subgroup analyses of site-specific malignancies based on the data from four trials, the risk of bladder cancer with pioglitazone (MH-OR) was 2.05 [0.84–5.02]; p = 0.12. Further, rosiglitazone, but not pioglitazone, was associated with a significantly reduced risk of bowel cancer. In contrast, pioglitazone, but not rosiglitazone, was associated with a significant reduction in breast cancer. The present meta-analysis of trials, not designed a priori to test the hypothesis, provides reassuring evidence that TZDs are not associated with risk of overall malignancies. In fact, they are compatible with the possibility of a decreased risk of cancer. In site-specific subgroup analyses, for rosiglitazone, there was a significant decreased risk of bowel cancer. Subgroup analyses for pioglitazone did not allow to exclude an increased risk of bladder cancer, while the risk of breast cancer was significantly decreased. While these data are also useful to formulate not test hypotheses, they provide somewhat more cogent evidence than the previously published epidemiological data.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, pubmed, cancer, google, scholar, diabetes, cas, pioglitazone, risk, patients, bladder, rosiglitazone, type, metaanalysis, randomized, trials, drug, data, thiazolidinediones, study, clinical, monami, mannucci, safety, care, trial, access, privacy, cookies, content, information, acta, test, significant, effects, agency, european, publish, research, search, results, published, matteo, dicembrini, edoardo, malignancies, tzds, mhor, subgroup, analyses,

Topics {✒️}

eu/docs/en_gb/document_library/press_release/2010/07/wc500094981 month download article/chapter gov/drugs/drugsafety/ucm226214 azienda ospedaliero-universitaria careggi parallel-group comparison trial lewis jd open-label trial site-specific subgroup analyses ppargamma-independent antitumor effects site-specific malignancies based ongoing benefit-risk review european medicines agency full article pdf privacy choices/manage cookies author information authors performed including published oral antidiabetic medication related subjects edoardo mannucci article monami anti-diabetic agents hepatology [epub ahead european economic area oral hypoglycaemic agents randomized clinical trials preferred reporting items ongoing safety review careggi teaching hospital randomised controlled trial population-based study unpublished randomized trials active comparator groups quesenberry cp jr secondary prevention versican g3 domain impaired glucose tolerance impaired fasting glucose acid-forming diet bristol myers squibb ilaria dicembrini comparator-controlled study present meta-analysis meta-analysis detected received consultancy fees conditions privacy policy check access instant access long-term comparison ppargamma-independent induction case-control study

Questions {❓}

Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
         description:Recent epidemiological data have contributed to the formulation of the hypothesis about the long-term safety of pioglitazone, a thiazolidinedione (TZD), with respect to malignancies, in particular bladder cancer. The primary aim of this meta-analysis of randomized clinical trials, not designed a priori to test this hypothesis, was to explore whether TZDs affect the risk of cancer. A meta-analysis was performed including published and unpublished randomized trials with a duration of at least 52 weeks, enrolling patients with or without diabetes, comparing TZDs with either placebo or other drug therapies on various different outcomes. We found 22 trials reporting at least one cancer and enrolling 13,197 patients to TZD (pioglitazone: n = 3,710 and rosiglitazone: n = 9,487) and 12,359 to placebo or active comparator groups. The mean follow-up was 26.1 months. Overall, those assigned at random to TZDs had a significant reduction (MH-OR 0.85 [0.73–0.98]; p = 0.027) in the incidence of malignancies, with no significant difference in effect between pioglitazone and rosiglitazone. Specifically, subgroup analyses showed a significant reduction for rosiglitazone (MH-OR 0.82 [0.69–0.98]; p = 0.029), but not for pioglitazone (MH-OR 0.66 [0.34–1.28]; p = 0.22). In further subgroup analyses of site-specific malignancies based on the data from four trials, the risk of bladder cancer with pioglitazone (MH-OR) was 2.05 [0.84–5.02]; p = 0.12. Further, rosiglitazone, but not pioglitazone, was associated with a significantly reduced risk of bowel cancer. In contrast, pioglitazone, but not rosiglitazone, was associated with a significant reduction in breast cancer. The present meta-analysis of trials, not designed a priori to test the hypothesis, provides reassuring evidence that TZDs are not associated with risk of overall malignancies. In fact, they are compatible with the possibility of a decreased risk of cancer. In site-specific subgroup analyses, for rosiglitazone, there was a significant decreased risk of bowel cancer. Subgroup analyses for pioglitazone did not allow to exclude an increased risk of bladder cancer, while the risk of breast cancer was significantly decreased. While these data are also useful to formulate not test hypotheses, they provide somewhat more cogent evidence than the previously published epidemiological data.
         datePublished:2013-07-14T00:00:00Z
         dateModified:2013-07-14T00:00:00Z
         pageStart:91
         pageEnd:101
         sameAs:https://doi.org/10.1007/s00592-013-0504-8
         keywords:
            Thiazolidinediones
            Cancer
            Type 2 diabetes
            Internal Medicine
            Diabetes
            Metabolic Diseases
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig4_HTML.gif
         isPartOf:
            name:Acta Diabetologica
            issn:
               1432-5233
               0940-5429
            volumeNumber:51
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Milan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Matteo Monami
               affiliation:
                     name:Careggi Teaching Hospital
                     address:
                        name:Geriatric Cardiology, Careggi Teaching Hospital, Florence, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ilaria Dicembrini
               affiliation:
                     name:Careggi Teaching Hospital
                     address:
                        name:Obesity Agency, Careggi Teaching Hospital, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Edoardo Mannucci
               affiliation:
                     name:Azienda Ospedaliero-Universitaria Careggi
                     address:
                        name:Diabetes Agency, Careggi Teaching Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
      description:Recent epidemiological data have contributed to the formulation of the hypothesis about the long-term safety of pioglitazone, a thiazolidinedione (TZD), with respect to malignancies, in particular bladder cancer. The primary aim of this meta-analysis of randomized clinical trials, not designed a priori to test this hypothesis, was to explore whether TZDs affect the risk of cancer. A meta-analysis was performed including published and unpublished randomized trials with a duration of at least 52 weeks, enrolling patients with or without diabetes, comparing TZDs with either placebo or other drug therapies on various different outcomes. We found 22 trials reporting at least one cancer and enrolling 13,197 patients to TZD (pioglitazone: n = 3,710 and rosiglitazone: n = 9,487) and 12,359 to placebo or active comparator groups. The mean follow-up was 26.1 months. Overall, those assigned at random to TZDs had a significant reduction (MH-OR 0.85 [0.73–0.98]; p = 0.027) in the incidence of malignancies, with no significant difference in effect between pioglitazone and rosiglitazone. Specifically, subgroup analyses showed a significant reduction for rosiglitazone (MH-OR 0.82 [0.69–0.98]; p = 0.029), but not for pioglitazone (MH-OR 0.66 [0.34–1.28]; p = 0.22). In further subgroup analyses of site-specific malignancies based on the data from four trials, the risk of bladder cancer with pioglitazone (MH-OR) was 2.05 [0.84–5.02]; p = 0.12. Further, rosiglitazone, but not pioglitazone, was associated with a significantly reduced risk of bowel cancer. In contrast, pioglitazone, but not rosiglitazone, was associated with a significant reduction in breast cancer. The present meta-analysis of trials, not designed a priori to test the hypothesis, provides reassuring evidence that TZDs are not associated with risk of overall malignancies. In fact, they are compatible with the possibility of a decreased risk of cancer. In site-specific subgroup analyses, for rosiglitazone, there was a significant decreased risk of bowel cancer. Subgroup analyses for pioglitazone did not allow to exclude an increased risk of bladder cancer, while the risk of breast cancer was significantly decreased. While these data are also useful to formulate not test hypotheses, they provide somewhat more cogent evidence than the previously published epidemiological data.
      datePublished:2013-07-14T00:00:00Z
      dateModified:2013-07-14T00:00:00Z
      pageStart:91
      pageEnd:101
      sameAs:https://doi.org/10.1007/s00592-013-0504-8
      keywords:
         Thiazolidinediones
         Cancer
         Type 2 diabetes
         Internal Medicine
         Diabetes
         Metabolic Diseases
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-013-0504-8/MediaObjects/592_2013_504_Fig4_HTML.gif
      isPartOf:
         name:Acta Diabetologica
         issn:
            1432-5233
            0940-5429
         volumeNumber:51
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Milan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Matteo Monami
            affiliation:
                  name:Careggi Teaching Hospital
                  address:
                     name:Geriatric Cardiology, Careggi Teaching Hospital, Florence, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ilaria Dicembrini
            affiliation:
                  name:Careggi Teaching Hospital
                  address:
                     name:Obesity Agency, Careggi Teaching Hospital, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Edoardo Mannucci
            affiliation:
                  name:Azienda Ospedaliero-Universitaria Careggi
                  address:
                     name:Diabetes Agency, Careggi Teaching Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Acta Diabetologica
      issn:
         1432-5233
         0940-5429
      volumeNumber:51
Organization:
      name:Springer Milan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Careggi Teaching Hospital
      address:
         name:Geriatric Cardiology, Careggi Teaching Hospital, Florence, Italy
         type:PostalAddress
      name:Careggi Teaching Hospital
      address:
         name:Obesity Agency, Careggi Teaching Hospital, Florence, Italy
         type:PostalAddress
      name:Azienda Ospedaliero-Universitaria Careggi
      address:
         name:Diabetes Agency, Careggi Teaching Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Matteo Monami
      affiliation:
            name:Careggi Teaching Hospital
            address:
               name:Geriatric Cardiology, Careggi Teaching Hospital, Florence, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ilaria Dicembrini
      affiliation:
            name:Careggi Teaching Hospital
            address:
               name:Obesity Agency, Careggi Teaching Hospital, Florence, Italy
               type:PostalAddress
            type:Organization
      name:Edoardo Mannucci
      affiliation:
            name:Azienda Ospedaliero-Universitaria Careggi
            address:
               name:Diabetes Agency, Careggi Teaching Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Geriatric Cardiology, Careggi Teaching Hospital, Florence, Italy
      name:Obesity Agency, Careggi Teaching Hospital, Florence, Italy
      name:Diabetes Agency, Careggi Teaching Hospital, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(147)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.48s.

LINK . SPRINGER . COM {}